community have argued that making antiretroviral therapy available in resourcelimited settings would not be feasible or would not be a good public policy investment, data emerged very quickly after pilot programs were initiated that refuted this data-free speculation [3]. When treated with potent combinations of antiretroviral drugs in settings where appropriate adherence support can be provided, viral suppression rates very similar to those observed in high-resource settings can be achieved [3]. Initial efforts to deliver antiretroviral drugs in resource-limited settings were not unlike those ob
No takes yet. Share an insight, caveat, or question.
Robert T. Schooley (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: